ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$13.69
arrow_downward
-0.07%(-0.010) 1D
$13.69
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 30, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARCT...
Open
$13.80
High
$14.06
Low
$13.52
Mkt. cap
389.11M
Avg. vol.
1.34M
Volume
0.00
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
Open
$13.80
High
$14.06
Low
$13.52
Mkt. cap
389.11M
Avg. vol.
1.34M
Volume
0.00
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
News stories
From web sources and news partners
Seeking Alpha
·
21 minutes ago
Nasdaq rises nearly 2% in September, helped by late-month tech rally (AMD:NASDAQ)
MarketBeat
·
11 minutes ago
Lantronix (NASDAQ:LTRX) Stock Breaks Above 200-Day Moving Average - Time to Sell?
marketscreener.com
·
11 minutes ago
Accelevation struggles to convince on its Nasdaq debut
Investor's Business Daily
·
3 hours ago
Dow Jones Futures: Micron Earnings Crush Views, S&P 500 At Critical Level As Treasury Yields Rise
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc